Cravath’s New York Office Moves to Two Manhattan West
Christopher J. Kelly has a broad banking practice, with experience in syndicated lending, finance and related matters for both financial lending institutions and corporate borrowers.
Mr. Kelly’s representative matters have included:
Mr. Kelly has been recognized by Lawdragon as among the “500 Leading Dealmakers in America.”
Mr. Kelly was born in Mount Kisco, New York. He received a B.A. summa cum laude from Columbia University in 1996, where he was elected to Phi Beta Kappa, and a J.D. from Harvard Law School in 1999, where he was Supervising Editor of the Journal on Legislation.
Mr. Kelly joined Cravath in 1999 and was elected a partner in 2022.
Mr. Kelly’s representative matters have included:
Mr. Kelly has been recognized by Lawdragon as among the “500 Leading Dealmakers in America.”
Mr. Kelly was born in Mount Kisco, New York. He received a B.A. summa cum laude from Columbia University in 1996, where he was elected to Phi Beta Kappa, and a J.D. from Harvard Law School in 1999, where he was Supervising Editor of the Journal on Legislation.
Mr. Kelly joined Cravath in 1999 and was elected a partner in 2022.
American Bar Association
Lawdragon
Deals & Cases
October 29, 2024
Cravath represented Gannett Holdings LLC in connection with its $900 million senior secured term loan facility. Gannett Holdings LLC is a wholly owned subsidiary of Gannett Co., Inc., a leading diversified media company with expansive reach at the national and local level dedicated to empowering and enriching communities. The transaction closed on October 15, 2024.
Deals & Cases
August 22, 2024
Cravath represented QUALCOMM Incorporated in connection with its $4 billion revolving credit. QUALCOMM Incorporated is a global leader in the development and commercialization of foundational technologies for the wireless industry. The transaction closed on August 8, 2024.
Deals & Cases
June 24, 2024
On June 24, 2024, Illumina, Inc. (“Illumina”), a global leader in DNA sequencing and array-based technologies, announced the successful completion of the spin-off of GRAIL, a healthcare company whose mission is to detect cancer early. This follows Illumina’s previously announced plans to divest GRAIL, and GRAIL is now a public and independent company. The separation was achieved through the distribution of 85.5% of the outstanding shares of GRAIL to holders of Illumina common stock on June 24, 2024. In addition to retaining their shares of Illumina common stock, Illumina shareholders received one share of GRAIL common stock for every six shares of Illumina stock held as of close of business on the record date of June 13, 2024. Illumina retained 14.5% of the outstanding shares of GRAIL common stock. Cravath represented Illumina in connection with the transaction.
Deals & Cases
May 07, 2024
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
Deals & Cases
December 18, 2023
On December 18, 2023, ZimVie Inc. (“ZimVie”), a global life sciences leader in the dental and spine markets, announced it has entered into a definitive agreement to sell its spine business to H.I.G. Capital, a leading global alternative investment firm. Under the terms of the agreement, upon the closing of the transaction, ZimVie will receive $375 million in total consideration, comprised of $315 million in cash, subject to certain customary adjustments as set forth in the agreement, and $60 million in the form of a promissory note that will accrue interest at a rate of 10% per annum, compounded semi‑annually, payable in kind. Cravath is representing ZimVie in connection with the transaction.
Christopher J. Kelly has a broad banking practice, with experience in syndicated lending, finance and related matters for both financial lending institutions and corporate borrowers.
Mr. Kelly’s representative matters have included:
Mr. Kelly has been recognized by Lawdragon as among the “500 Leading Dealmakers in America.”
Mr. Kelly was born in Mount Kisco, New York. He received a B.A. summa cum laude from Columbia University in 1996, where he was elected to Phi Beta Kappa, and a J.D. from Harvard Law School in 1999, where he was Supervising Editor of the Journal on Legislation.
Mr. Kelly joined Cravath in 1999 and was elected a partner in 2022.
Mr. Kelly’s representative matters have included:
Mr. Kelly has been recognized by Lawdragon as among the “500 Leading Dealmakers in America.”
Mr. Kelly was born in Mount Kisco, New York. He received a B.A. summa cum laude from Columbia University in 1996, where he was elected to Phi Beta Kappa, and a J.D. from Harvard Law School in 1999, where he was Supervising Editor of the Journal on Legislation.
Mr. Kelly joined Cravath in 1999 and was elected a partner in 2022.
American Bar Association
Lawdragon
Deals & Cases
October 29, 2024
Cravath represented Gannett Holdings LLC in connection with its $900 million senior secured term loan facility. Gannett Holdings LLC is a wholly owned subsidiary of Gannett Co., Inc., a leading diversified media company with expansive reach at the national and local level dedicated to empowering and enriching communities. The transaction closed on October 15, 2024.
Deals & Cases
August 22, 2024
Cravath represented QUALCOMM Incorporated in connection with its $4 billion revolving credit. QUALCOMM Incorporated is a global leader in the development and commercialization of foundational technologies for the wireless industry. The transaction closed on August 8, 2024.
Deals & Cases
June 24, 2024
On June 24, 2024, Illumina, Inc. (“Illumina”), a global leader in DNA sequencing and array-based technologies, announced the successful completion of the spin-off of GRAIL, a healthcare company whose mission is to detect cancer early. This follows Illumina’s previously announced plans to divest GRAIL, and GRAIL is now a public and independent company. The separation was achieved through the distribution of 85.5% of the outstanding shares of GRAIL to holders of Illumina common stock on June 24, 2024. In addition to retaining their shares of Illumina common stock, Illumina shareholders received one share of GRAIL common stock for every six shares of Illumina stock held as of close of business on the record date of June 13, 2024. Illumina retained 14.5% of the outstanding shares of GRAIL common stock. Cravath represented Illumina in connection with the transaction.
Deals & Cases
May 07, 2024
On May 7, 2024, Ashland Inc. (“Ashland”), a global additives and specialty ingredients company, announced that it has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners LLC. Cravath is representing Ashland in connection with the transaction.
Deals & Cases
December 18, 2023
On December 18, 2023, ZimVie Inc. (“ZimVie”), a global life sciences leader in the dental and spine markets, announced it has entered into a definitive agreement to sell its spine business to H.I.G. Capital, a leading global alternative investment firm. Under the terms of the agreement, upon the closing of the transaction, ZimVie will receive $375 million in total consideration, comprised of $315 million in cash, subject to certain customary adjustments as set forth in the agreement, and $60 million in the form of a promissory note that will accrue interest at a rate of 10% per annum, compounded semi‑annually, payable in kind. Cravath is representing ZimVie in connection with the transaction.
Celebrating 200 years of partnership. In 2019, we celebrated our bicentennial. Our history mirrors that of our nation. Integral to our story is our culture.
Attorney Advertising. ©2024 Cravath, Swaine & Moore LLP.